Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chubb
Julphar
Cipla
Dow
QuintilesIMS
Healthtrust
US Army
Merck

Generated: November 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020718

« Back to Dashboard

NDA 020718 describes INTEGRILIN, which is a drug marketed by Schering and is included in one NDA. It is available from one supplier. Additional details are available on the INTEGRILIN profile page.

The generic ingredient in INTEGRILIN is eptifibatide. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the eptifibatide profile page.
Summary for 020718
Tradename:INTEGRILIN
Applicant:Schering
Ingredient:eptifibatide
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020718
Physiological EffectDecreased Platelet Aggregation
Suppliers and Packaging for NDA: 020718
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718 NDA Merck Sharp & Dohme Corp. 0085-1136 0085-1136-03 1 VIAL, SINGLE-USE in 1 CARTON (0085-1136-03) > 100 mL in 1 VIAL, SINGLE-USE
INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718 NDA Merck Sharp & Dohme Corp. 0085-1136 0085-1136-01 1 VIAL, SINGLE-USE in 1 CARTON (0085-1136-01) > 100 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength2MG/ML
Approval Date:May 18, 1998TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength75MG/100ML
Approval Date:May 18, 1998TE:APRLD:Yes

Expired US Patents for NDA 020718

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Sign Up ➤ Sign Up
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Sign Up ➤ Sign Up
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Sign Up ➤ Sign Up
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-002 May 18, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
US Army
Queensland Health
Colorcon
Deloitte
McKinsey
Citi
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.